TMCnet News
WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018WAVE (News - Alert) Life Sciences Ltd. (NASDAQ: WVE), a genetic medicine company focused on advancing potential best-in-class stereopure nucleic acid therapies, today announced its plan to deliver six clinical programs by 2018. The announcement follows WAVE's successful initial public offering in November 2015, in which the company raised approximately $112 million in gross proceeds, bringing the total capital closed in 2015 to approximately $196 million. "Over the next three years, WAVE plans to bring multiple novel therapies into the clinic, offering new hope to patients with rare diseases and their caregivers," said Paul Bolno, M.D., MBA, President and Chief Executive Officer at WAVE Life Sciences. "We believe that we have the leading genetic medicines platform and continue to build both the team and the infrastructure to execute on our vision." To support its ambitious goals, WAVE's plan includes:
About WAVE Life Sciences WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. Given the versatility of its chemistry platform, WAVE's pipeline is designed to span multiple oligonucleotide modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com and follow us on Twitter and LinkedIn. This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following: our filing of INDs and commencing clinical trials; the future performance and results of our programs in clinical trials; our identification of future candidates and their therapeutic potential; the anticipated therapeutic benefits of stereopure therapies compared to other therapies; our advancing of therapies across multiple modalities and the anticipated benefits of that strategy; our future growth; the potential of our stereopure approach and nucleic acid therapeutics; and our cash position supporting our anticipated business activities. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the following: the ability of our preclinical programs to produce data sufficient to support the filing of INDs and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results of our programs, which may not support further development of product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical studies; our effectiveness in managing future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to raise additional capital as needed; and competition from others developing therapies for similar uses, as well as the information under the caption "Risk Factors" contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC (News - Alert)) and in other filings we make with the SEC. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005228/en/ |